Monday, April 16, 2012 - 01:00

Burton-on-Trent, UK–16 April 2012

Clinigen Global Access Programs (Clinigen GAP), a division of Clinigen Group, today announced an agreement with Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX:VRX), a multinational specialty pharmaceutical company, under which Clinigen GAP will distribute certain orphan and ophthalmic drugs of Valeant, on a named patient basis, to patients outside the US and Canada.

Under a named-patient program (NPP), licensed healthcare professionals can legally prescribe an investigational or pre-approval drug to qualifying patients on an individual basis prior to the product receiving regulatory approval in the countries concerned.

“We are delighted that Valeant has selected Clinigen GAP to manage this portfolio of named-patient programs, providing access to a number of speciality products to patients with no therapeutic alternative,” said Mark Corbett, vice-president of Clinigen GAP. “Our team has extensive experience of developing innovative, flexible and bespoke named-patient programs that meet the necessary regulatory requirements of each individual territory and address the needs of patients, health professionals and biopharmaceutical companies. We look forward to working with Valeant in the future.”

The new agreement will take immediate effect. Valeant retains all rights to the products in the US and Canada.

Licensed healthcare professionals working outside the US and Canada may contact Clinigen directly on +44 1283 494 340 or by emailing

About Clinigen GAP

Clinigen is a fast-growing global specialty pharmaceutical products and services business dedicated to serving patients, the medical community and the healthcare industry. Clinigen’s Global Access Programs division (Clinigen GAP) specializes in the consultancy, development, management and implementation of Global Access Programs for biotechnology and pharmaceutical companies.

Clinigen’s innovative, bespoke programs provide a fully outsourced solution for managing access to unlicensed, licensed or end-of-lifecycle products. Clinigen understands the value of products to a company and the importance of protecting and maximizing the long-term value of assets through Global Access Programs. Clinigen’s highly dedicated, multilingual and experienced team effectively manages client and product needs. Clinigen has proven management experience of implementing over 30 programs, providing access for thousands of patients globally.

For more information, please visit

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at

Media contacts

Pete Chan at Tudor Reilly 
Office: +44(0) 207 034 208 
Mobile: +44(0)7725 554 632



Back to News